Cambridge Advisors Inc. grew its position in Amgen, Inc. (NASDAQ:AMGN) by 0.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,875 shares of the medical research company’s stock after buying an additional 96 shares during the quarter. Amgen accounts for 1.9% of Cambridge Advisors Inc.’s holdings, making the stock its 8th largest holding. Cambridge Advisors Inc.’s holdings in Amgen were worth $5,232,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the business. Arlington Partners LLC lifted its stake in shares of Amgen by 86.7% during the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after purchasing an additional 65 shares during the last quarter. Massey Quick Simon & CO. LLC lifted its stake in shares of Amgen by 710.5% during the 4th quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock worth $30,000 after purchasing an additional 135 shares during the last quarter. Contravisory Investment Management Inc. purchased a new stake in shares of Amgen during the 4th quarter worth $50,000. Lavaca Capital LLC purchased a new stake in shares of Amgen during the 4th quarter worth $78,000. Finally, Moody National Bank Trust Division purchased a new stake in shares of Amgen during the 4th quarter worth $81,000. Institutional investors and hedge funds own 81.79% of the company’s stock.
Shares of AMGN stock opened at $188.98 on Thursday. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36. The stock has a market capitalization of $119.31 billion, a PE ratio of 13.12, a PEG ratio of 2.06 and a beta of 1.21. Amgen, Inc. has a fifty-two week low of $163.31 and a fifty-two week high of $210.19.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a $1.45 dividend. The ex-dividend date of this dividend is Thursday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.32. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.07%. Amgen’s dividend payout ratio is currently 36.67%.
Several research analysts recently issued reports on AMGN shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $220.00 target price on shares of Amgen in a research report on Tuesday, December 4th. Morgan Stanley reaffirmed a “buy” rating and set a $213.00 target price on shares of Amgen in a research report on Tuesday, December 4th. Goldman Sachs Group reaffirmed a “buy” rating and set a $232.00 target price on shares of Amgen in a research report on Tuesday, December 4th. Oppenheimer set a $224.00 target price on Amgen and gave the company a “buy” rating in a research report on Tuesday, October 30th. Finally, Mizuho reaffirmed a “buy” rating and set a $206.00 target price on shares of Amgen in a research report on Friday, October 26th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $205.77.
In other news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $190.00, for a total value of $380,000.00. Following the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at $2,847,720. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tyler Jacks sold 20,000 shares of the stock in a transaction dated Thursday, December 6th. The shares were sold at an average price of $195.41, for a total value of $3,908,200.00. Following the completion of the transaction, the director now directly owns 28,979 shares in the company, valued at $5,662,786.39. The disclosure for this sale can be found here. Insiders sold 23,777 shares of company stock worth $4,648,718 over the last three months. Corporate insiders own 0.27% of the company’s stock.
WARNING: This news story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2019/02/14/amgen-inc-amgn-shares-bought-by-cambridge-advisors-inc.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Story: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.